Blueprint Medicines Corp (NASDAQ:BPMC) stock price target upped to $31.00, issued a report today by Zacks Investment Research
- Updated: October 7, 2016
Blueprint Medicines Corp (NASDAQ:BPMC) had its price target upped to $31.00 by Zacks Investment Research in an issued report announced 10/07/2016. The updated stock price target implies a possible upside of 0.12% based on the company's most recent stock price close.
Boasting a price of $27.74, Blueprint Medicines Corp (NASDAQ:BPMC) traded 3.58% higher on the day. With the last stock price close up 29.01% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. BPMC has recorded a 50-day average of $27.92 and a two hundred day average of $21.50. Trade Volume was down over the average, with 130,508 shares of BPMC changing hands under the typical 180,442
With a total market value of $0, Blueprint Medicines Corp has with a 52 week low of $13.04 and a 52 week high of $29.90 .
In addition to Zacks Investment Research reporting its stock price target, a total of 3 brokers have issued a research note on the company. The average stock price target is $31.00 with 1 brokerage rating the stock a strong buy, 2 brokerages rating the stock a buy, 1 brokerage rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Blueprint Medicines Corp (NASDAQ:BPMC)
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options. The Company has developed a small molecule drug pipeline in cancer and a genetic disease. The Company's drug candidate, BLU-285, targets KIT Exon 17 mutants and PDGFRa D842V, which are abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. It is engaged in developing BLU-285 for patients with systemic mastocytosis (SM), a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor (GIST). Its drug candidate, BLU-554, targets FGFR4, a kinase that is aberrantly activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma (HCC).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.